Experience with PEP finds most patients stop early.
D019380:Anti-HIV Agents / Q000627:therapeutic use; D001955:British Columbia; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D006297:Health Services Accessibility; D018451:Homosexuality, Male; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D009784:Occupational Diseases / Q000188:drug therapy / Q000517:prevention & control*; D010349:Patient Compliance; D012749:Sexually Transmitted Diseases / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D013997:Time Factors; D014481:United States; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine